

# GSK makes strong start to 2025 with growth in sales, profits and earnings

“GSK continues to make strong progress, demonstrating the quality, strength and resilience of our portfolio. Specialty Medicines, our largest business, delivered strong sales contributions in the quarter and R&D progress continued, with two of the five FDA product approvals expected this year now secured, and the acquisition of a promising new oncology asset. We are very focused on preparing for launches of *Blenrep*, *Nucala* and depemokimab, and pivotal trials for potential new medicines in respiratory, oncology, HIV and hepatitis. This momentum, together with the strength of our portfolio and proven ability to drive operating leverage, underpin our confidence in guidance for the year and our longer-term outlooks.”

Emma Walmsley  
Chief Executive Officer, GSK



## Specialty Medicines

£2.9bn +17%

Respiratory, Immunology and Inflammation +28%  
Oncology +53% HIV +7%

## Vaccines

£2.1bn -6%

## General Medicines

£2.5bn +0%

Core operating profit

£2.5bn

+5%

Total EPS

39.7p

+56%

Core EPS

44.9p

+5%

Dividend Q1

16p

5

major new FDA product approvals expected in 2025

14

key opportunities expected to launch 2025-2031

70

medicines and vaccines in pipeline

18

pipeline assets in phase III / registration

Journalists/media see press release on [www.gsk.com](http://www.gsk.com) for full details on Q1 2025.  
Please read the cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measures on pages 46 and 47 of the press release.  
Product group sales may not add to total sales due to rounding.  
References to growth are at constant exchange rates (CER) unless stated otherwise.



Ahead Together